Authors
Qiang Yang, Yuyang He, Lejia Wang, Xiaoxia Yuan, Jingping Zhang, Jinxin Chen, Guohui Jiang, Wenrong Ma, Xingtong Lu, Chen Wei, Bin Zhang, Shihao Deng, Yaomin Luo, Yang Xiao, Kexun Long, Chaoying Xu, Xinqiang Yin, Zhen Jiang
Published in
European journal of pharmacology. Pages 179339. Sep 10, 2026. Epub Sep 10, 2026.
Abstract
Previous work has indicated that lipid metabolic reprogramming plays a critical role in gastric cancer (GC) development, yet the underlying molecular mechanisms remain largely undefined. In the present study, we identified a novel lipid metabolism-associated long non-coding RNA, 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (lncHMGCS1), which is aberrantly upregulated in GC tissues and cell lines. Functional assays demonstrated that lncHMGCS1 overexpression could promote intracellular lipid droplet accumulation, elevate the triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, and enhance GC cell proliferation. Mechanistically, lncHMGCS1 can suppress expression of miR-18b-5p, a microRNA that directly targets both lncHMGCS1 and acyl-CoA synthetase long-chain family member 3 (ACSL3). ACSL3 knockdown reversed the oncogenic effects of lncHMGCS1 on GC cells in a miR-18b-5p-dependent manner, highlighting the critical role of the lncHMGCS1-ACSL3 axis in lipid metabolic reprogramming. Collectively, our findings establish lncHMGCS1 as a driver of lipid metabolism and tumorigenesis in GC, laying the groundwork for the development of novel diagnostic and therapeutic targets for managing this disease.
PMID:
42722057
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0